Simplify Logo

Full-Time

Director – Tax

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$226k - $255kAnnually

+ Equity Component

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Tax Accounting
Accounting
Requirements
  • Minimum of 12 years’ experience in tax function of a public company with a global presence (a minimum of five of which should be in a management position), is required. Bachelor's degree in Accounting, Tax or Finance and CPA license, is required.
  • Previous experience leading tax and demonstrated ability to manage a variety of domestic and international tax matters, compliance, indirect tax, transfer pricing, VAT, sales and payroll tax matters independently and have the capability to dissect specialized matters and analysis inform decision making.
  • Strong knowledge of US GAAP, internal controls/SOX and financial reporting requirements in a public company setting, is required.
  • Experience in fast-paced environment, highly driven with the ability to conduct multiple tasks and meet deadlines.
  • Outstanding organizational, problem-solving, and analytical skills.
  • Attention to detail without losing sight of the big picture.
  • Demonstrated ability to plan and organize projects, especially long-term.
  • Able to manage multiple complex projects and deliver in a timely manner.
  • Effectively communicates and presents information to senior management and other stakeholders (written, orally and via presentation materials), possesses an inquisitive mind, and works effectively with multiple functions; brings strong executive presence and the ability to influence decision making.
  • The ideal candidate will be a results-driven team player and must thrive in a fast-paced, dynamic environment. He/ She must have the ability to drive results, possesses a strong drive to meet and exceed goals and is willing to take ownership of problems and make or recommend sound decisions.
  • The candidate will be an independent self-starter and a proactive leader who is continually focused on building a high performing team.
  • Ability to work onsite 3 days per week required; and more often based on business needs.
  • Embodies Vaxcyte’s cultural attributes: caring, courage, excellence and passion.
Responsibilities
  • Oversee U.S. federal, state and international tax compliance process, including indirect taxes, subpart F income, GILTI, R&D and foreign tax credits, VAT matters and expense allocations.
  • Provide strategic direction, technical guidance, and leadership on all tax matters impacting the company.
  • Partner and manage the relationships with external tax advisors and internal stakeholders.
  • Reviews tax returns and related documents to ensure compliance with federal, state and international laws. Authorizes the payment of taxes due. Manages audits when applicable.
  • Works closely with Accounting to provide inputs for policy setting, review of business results in monthly/quarterly reporting cycles and forecasts.
  • Advises management of the impact of new tax laws and proposed legislation.
  • Pursues refunds, credits and incentives as the company moves into new markets or new locations to maximize tax benefits to the company.
  • Review annual and quarterly tax provisions and related disclosures in our SEC filings.
  • Oversee preparation of worldwide transfer pricing documentation, including master file, local files, and country by country reporting.
  • Recognize complex technical tax issues, perform research and analysis to support management decision-making.
  • Other special projects and assignments as required.
  • Exercise judgment in selecting methods, techniques and evaluation criteria for obtaining optimal results.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to protect vulnerable populations from serious bacterial infections.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

61%

2 year growth

125%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.